Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855230 | 0.82 | KDM1A (0.48) | KDM1AKCNH2KDM1B | |
| SCHEMBL5513611 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL29666934 | 0.82 | KDM1A (0.48) | KDM1AKCNH2KDM1B | |
| SCHEMBL29386666 | 0.81 | KDM1A (0.38) | KDM1AKCNH2KDM1BAXLALDH1A1 | |
| SCHEMBL239637 | 0.81 | KDM1A (0.38) | KDM1AKCNH2KDM1BAXLALDH1A1 | |
| SCHEMBL38652629 | 0.81 | AXL (0.34) | KDM1AKCNH2KDM1BAXLALDH1A1 | |
| SCHEMBL150967 | 0.77 | CYP3A4 (0.40) | KDM1AKCNH2KDM1BAXLALDH1A1 | |
| SCHEMBL159571 | 0.77 | PTGER4 (0.33) | KDM1AKCNH2KDM1BAXLALDH1A1 | |
| SCHEMBL19405866 | 0.77 | KDM1A (0.35) | KDM1AKCNH2KDM1BAXLALDH1A1 | |
| SCHEMBL21815082 | 0.77 | KDM1A (0.35) | KDM1AKCNH2KDM1BAXLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090048305-A1 | Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2009-02-19 | — | — | US | disclosed |
| US-20090048305-A1 | Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections | SHANGHAI MICURX PHARMACEUTICAL CO. LTD. (CN) | 2009-02-19 | — | — | US | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
| EP-0224001-B1 | ANTHRANILONITRILE DERIVATIVES AND RELATED COMPOUNDS AS USEFUL AGENTS FOR PROMOTING GROWTH, IMPROVING FEED EFFICIENCY, AND FOR INCREASING THE LEAN MEAT TO FAT RATIO OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4863959-A | Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0224001-A1 | Anthranilonitrile derivatives and related compounds as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | KDM1A 2344/4885KCNH2 4691/4885KDM1B 1958/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | KDM1A 1879/4885KCNH2 2480/4885KDM1B 1644/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | KDM1A 414/4885KCNH2 2874/4885KDM1B 455/4885 |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CYP51A1, CYP11B2, CYP11B1 | KDM1A 4547/4885KCNH2 2513/4885KDM1B 4552/4885 |
| US-20090048305-A1 | Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections | OXA1L, OGFOD1, OLA1 | KDM1A 3589/4885KCNH2 2555/4885KDM1B 3628/4885 |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | KDM1A 1156/4885KCNH2 1317/4885KDM1B 1010/4885 |
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM3, CHRM4, CHRM2 | KDM1A 1916/4885KCNH2 242/4885KDM1B 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.